<DOC>
	<DOCNO>NCT01816113</DOCNO>
	<brief_summary>This open label phase Ia study , assess safety two novel malaria vaccine , ChAd63 PvDBP , without MVA PvDBP . Heterologous prime-boost ChAd63-MVA , knowledge , one potent T cell-inducing subunit vaccine regimens importantly also induce antibody . Previous clinical trial use regimen express ME-TRAP , AMA1 &amp; MSP1 , show administer ChAd63 prime follow 8 week later MVA boost immunogenic schedule ( 32-34 ) . For reason , provide comparability previous ChAd63-MVA trial , propose use similar administration schedule .</brief_summary>
	<brief_title>Phase Ia Study ChAd63/MVA PvDBP</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<criteria>Healthy adult age 18 50 year . Able willing ( Investigator 's opinion ) comply study requirement . Willing allow investigator discuss volunteer 's medical history General Practitioner . For female , willingness practice continuous effective contraception study negative pregnancy test day ( ) vaccination . Agreement refrain blood donation course study . Provide write informed consent . Participation another research study involve receipt investigational product 30 day precede enrolment , plan use study period . Prior receipt investigational malaria vaccine investigational vaccine likely impact interpretation trial data . Administration immunoglobulins and/or blood product within three month precede plan administration vaccine candidate . Any confirm suspected immunosuppressive immunodeficient state , include HIV infection ; asplenia ; recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) . History allergic disease reaction likely exacerbate component vaccine , e.g . egg product , Kathon . History clinically significant contact dermatitis . Any history anaphylaxis reaction vaccination . Pregnancy , lactation willingness/intention become pregnant study . History cancer ( except basal cell carcinoma skin cervical carcinoma situ ) . History serious psychiatric condition . Any serious chronic illness require hospital specialist supervision . Suspected known current alcohol abuse define alcohol intake great 42 unit every week . Suspected known inject drug abuse 5 year precede enrolment . Seropositive hepatitis B surface antigen ( HBsAg ) . Seropositive hepatitis C virus ( antibody HCV ) positive PCR hepatitis C screening . History clinical malaria ( specie ) . Travel malaria endemic region study period within previous six month . Any clinically significant abnormal find screen biochemistry haematology blood test urinalysis . Any significant disease , disorder finding may significantly increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data . Inability study team contact volunteer 's GP confirm medical history safety participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>PvDBP</keyword>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium vivax</keyword>
</DOC>